Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Schering-Plough, Shionogi to Comarket Antiallergic Claritin
January 29, 2001
- Phase III Comparative Study on Progressive Lung Cancer Begins
January 29, 2001
- Toho Ties Up with Tsuruhara Yoshii in Kumamoto
January 29, 2001
- Overall Mortality Increases at Total Cholesterol of 180 mg/dl or Less
January 29, 2001
- Santen Agrees with Nippon Organon to Develop, Manufacture, Market Glaucoma Treatment
January 29, 2001
- Novartis 5-Generation Campaign Recruits 378 Families
January 29, 2001
- Sankyo Completes Purchase of Sankyo Parke Davis Stocks from Pfizer
January 29, 2001
- WHO GLs for Allergic Rhinitis Introduced at UCB Symposium
January 29, 2001
- Kuraya Sanseido Aims at Sales of \1.5 Trillion in Next Stage
January 29, 2001
- BI Establishes Virtual Research Institute of Aging
January 29, 2001
- EMA Dissatisfied with FPMAJ Policy Regarding Healthcare Reform
January 29, 2001
- GlaxoSmithKline Opens Call-Centre for Health Professionals, Patients
January 22, 2001
- 16 Ingredients to Be Added to Orange Book
January 22, 2001
- PDA International Congress to Be Held from Feb. 19 to 21
January 22, 2001
- Company Leaders Stress Importance of Globalization, IT Revolution
January 22, 2001
- REGULATORY NEWS IN BRIEF -1-
January 22, 2001
- Fujisawa to Reorganize European Operations
January 22, 2001
- Drug Industry Should Earn More Foreign Currency: Mr Fujiyama of FPMAJ
January 22, 2001
- REGULATORY NEWS IN BRIEF -2-
January 22, 2001
- FJPWA Opposes Harsher Changes in NHI Price Revision Rule: Mr Kojima
January 22, 2001
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…